Contrary to recent evidence, new research has found no positive correlation between anticholinergic medication intake and a higher risk for dementia in Parkinson’s disease (PD) patients. The study is titled “Anticholinergic Load: Is there a Cognitive Cost in Early Parkinson’s Disease?” and appears in the Journal…
News
Evidence has shown a potential connection between chronic hepatitis C virus (HCV) infection and neurological and psychiatric disorders such as Parkinson’s disease (PD). In a recent study, investigators sought to determine if the disease was, in fact, a significant risk factor for Parkinson’s development. Their findings, in a study…
A recent study shows that patients with Parkinson’s disease (PD) have a dysfunctional brain reward anticipation response — a finding likely linked to the decreased motivational state that can afflict PD patients. The deficit in dopaminergic signaling that underlies PD affects more than just motor skills. Depression, apathy, and sleep disorders also frequently…
Parkinson’s News Today regularly reports the latest news on clinical trials, state-of-the-art research, and events related to Parkinson’s disease. With 2015 at a close, Parkinson’s News Today brings you the past year’s Top 10 Parkinson’s Disease Stories as determined by the number of views given each article by readers. No.
Amarantus BioScience Holdings, Inc. (AMBS) received a Notice of Allowance from the U.S. Patent and Trademark Office covering the use of 5HT1A in combination with 5HT1B agonists, including the clinical Phase 2b stage drug eltoprazine, to treat levodopa-induced dyskinesia (PD-LID) in Parkinson’s disease (PD). The office issues such a…
University of Nebraska Medical Center and Longevity Biotech researchers demonstrated that LBT-3627, a novel drug candidate developed by the company, prevented nerve cell damage and protected dopamine-producing cells in a mouse model of Parkinson’s disease. The research paper, entitled “Selective VIP Receptor Agonists Facilitate Immune Transformation for Dopaminergic Neuroprotection in…
International Stem Cell Corporation announced that its subsidiary, Cyto Therapeutics, has been given regulatory permission to start a Phase 1/2a dose escalation clinical trial of its neural stem cells (ISC-hpNSC) in the treatment of Parkinson’s disease (PD). Clearance for the trial came the Therapeutics Goods Administration (TGA) of Australia. The trial will test…
A novel physiological role for mitochondria with implications in the study of age-related diseases such as Parkinson’s has been described. Researchers found that mitochondrial dysfunction in proliferating human cells induces senescence growth arrest and causes cells to secrete distinct secretory phenotypes. The research paper, titled “Mitochondrial Dysfunction Induces Senescence with a Distinct…
Researchers at the Department of Neurological Surgery at Case Western Reserve University School of Medicine and University Hospitals Case Medical Center recently received a $1 million grant to investigate the effectiveness of a diabetes drug for treating Parkinson’s disease. According to a press release from the…
A new study links a pesticide used prior to the early 1980s and milk consumed by adults during those years to substancia nigra neuronal death that is a hallmark of Parkinson’s disease. The research paper, titled “Midlife milk consumption and substantia nigra neuron density at death,” was published in Neurology, the journal…
Recent Posts
- Reducing disparities in care, research for women with Parkinson’s disease
- Ethics committee in the Netherlands green lights Parkinson’s clinical trial
- From a long-held wish to a labor of love
- Parkinson’s changed my uncle’s daily life, but his personality remained
- Developer targeting abnormal muscle tone in Parkinson’s with its VIM0423